Enzo Biochem (NYSE:ENZ) Posts Earnings Results

Enzo Biochem (NYSE:ENZ) issued its quarterly earnings data on Monday. The medical research company reported ($0.02) EPS for the quarter, Zacks reports. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.

Enzo Biochem Stock Down 4.7 %

NYSE:ENZ traded down $0.02 during trading hours on Monday, hitting $0.47. 14,227 shares of the company were exchanged, compared to its average volume of 118,049. Enzo Biochem has a 52-week low of $0.41 and a 52-week high of $1.30. The company’s 50 day moving average price is $0.57 and its 200-day moving average price is $0.88.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Enzo Biochem in a research note on Saturday. They set a “hold” rating for the company.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.